RARE - יחס שווי שוק להכנסות Ultragenyx Corp

The non-cyclical demand for genetic therapies makes the Ultragenyx Pharmaceutical (RARE) business resilient to crises, as confirmed by the current P/S level on the GURU.Markets service base chart, where the parameter mark equals 2.20. Its status as an exclusive provider of life-saving treatments guarantees high margins. Meanwhile, price stability is supported by the successful launch of new drugs and sufficient capital for clinical trials.
פילוחים אנליטיים של חברת Ultragenyx Corp (RARE)

The P/S ratio reflects the market value of a business relative to its annual revenue, allowing for an assessment of the premium paid per unit of sales. By analyzing the price/sales ratio trend, an investor can identify an overvaluation of Ultragenyx Pharmaceutical (RARE), which is critical given the current liquidity shortage and the company's high dependence on external financing due to costly R&D.